Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa study of MR001 in previously treated advanced triple-negative breast cancer
CTR20253893Phase 2Active
- Sponsor
- Medcare
- Start
- Jan 2026
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MR001 in triple-negative breast cancer (TNBC), sponsored by Medcare. Started Jan 2026; status: active.
02
Drugs
MR001
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20253893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253893.